Total Raised
$1.714BInvestors Count
18Deal Terms
3Funding, Valuation & Revenue
9 Fundings
Caris has raised $1.714B over 9 rounds.
Caris's latest funding round was a Loan for $400M on January 19, 2023.
Caris's valuation in May 2021 was $7,830M.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
1/19/2023 | Loan | $400M | 2 | |||
5/12/2021 | Private Equity - II | $7,830M | ||||
10/27/2020 | Private Equity | |||||
10/27/2020 | Debt - II | |||||
10/1/2018 | Convertible Note |
Date | 1/19/2023 | 5/12/2021 | 10/27/2020 | 10/27/2020 | 10/1/2018 |
|---|---|---|---|---|---|
Round | Loan | Private Equity - II | Private Equity | Debt - II | Convertible Note |
Amount | $400M | ||||
Investors | |||||
Valuation | $7,830M | ||||
Revenue | |||||
Sources | 2 |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Caris Deal Terms
3 Deal Terms
Caris's deal structure is available for 3 funding rounds, including their Private Equity - II from May 12, 2021.
Round | Private Equity - II | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Private Equity - II | |||||||||||||||
Series B | |||||||||||||||
Series A |
Caris Investors
18 Investors
Caris has 18 investors. OrbiMed Advisors invested in Caris's Loan funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/27/2020 | 1/19/2023 | 3 Private Equity, Private Equity - II (2021), Loan (2023) | Venture Capital | New York | ||
1/19/2023 | 1/19/2023 | 1 Loan | Corporation | Connecticut | ||
10/1/2018 | 5/12/2021 | 5 Convertible Note, Debt (2018), Private Equity (2020), Debt - II (2020), Private Equity - II (2021) | Asset/Investment Management | California | ||
Asset/Investment Management | New York | |||||
Asset/Investment Management | New York |
First funding | 10/27/2020 | 1/19/2023 | 10/1/2018 | ||
|---|---|---|---|---|---|
Last Funding | 1/19/2023 | 1/19/2023 | 5/12/2021 | ||
Investor | |||||
Rounds | 3 Private Equity, Private Equity - II (2021), Loan (2023) | 1 Loan | 5 Convertible Note, Debt (2018), Private Equity (2020), Debt - II (2020), Private Equity - II (2021) | ||
Board Seats | |||||
Type | Venture Capital | Corporation | Asset/Investment Management | Asset/Investment Management | Asset/Investment Management |
Location | New York | Connecticut | California | New York | New York |
Caris Acquisitions
1 Acquisition
Caris acquired 1 company. Their latest acquisition was Pharmatech on May 01, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
5/1/2019 | Acquired | 1 |
Date | 5/1/2019 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 1 |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Caris to Competitors
Genialis is an RNA biomarker company focused on advancing translational research and cancer drug development within the healthcare sector. The company specializes in discovering RNA biomarkers using machine learning, which aids in positioning oncology drugs, stratifying clinical trials, and developing diagnostic tests to predict patient responses and guide treatment decisions. Genialis collaborates with pharmaceutical and diagnostics companies to deliver precision medicine solutions that aim to improve clinical outcomes. It was founded in 2015 and is based in Boston, Massachusetts.
Px HealthCare is a company focused on improving health outcomes in the oncology sector by leveraging digital health platforms. The company offers a suite of tools designed to enhance patient experience and clinical outcomes, including personalized medical mobile support tools, real-world evidence collection, and remote patient monitoring systems. These products aim to empower patients with cancer by providing reliable information and practical support, facilitating informed decision-making and personalized care. It was founded in 2012 and is based in London, England.
KEW is a comprehensive genomic profiling company operating in the healthcare sector. The company's main service is providing therapeutic options for cancer care based on an individual patient's tumor genetic profile. KEW primarily sells to the healthcare industry, specifically molecular labs and physicians. KEW was formerly known as KEW Group. It was founded in 2011 and is based in Cambridge, Massachusetts.
Clarified Precision Medicine provides actionable treatment recommendations in the precision medicine sector, focusing on oncology. It offers treatment guidance, disease monitoring, and early cancer detection services, all informed by the molecular features of individual patients' tumors. It serves the healthcare industry, particularly oncologists and cancer care providers. It was founded in 2020 and is based in Tampa, Florida.
CancerIQ is a healthcare technology company that focuses on cancer prevention and early detection. It offers solutions that standardize risk assessment, track medical management changes, and automate documentation. Its services are primarily used in the healthcare sector, particularly by providers in oncology, genetics, breast centers, and preventive care. The company was founded in 2013 and is based in Chicago, Illinois.
OncoDNA is a genomic and theranostic company that specializes in precision medicine for cancer and genetic diseases within the healthcare sector. The company offers genomic profiling kits, clinical data intelligence, and biomarker testing services to facilitate personalized treatment and monitoring of patients. OncoDNA primarily serves oncology professionals, laboratory professionals, and pharma companies with its precision medicine solutions. It was founded in 2012 and is based in Gosselies, Belgium.
Loading...